Limits...
Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.

Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S - Cancer Sci. (2014)

Bottom Line: In addition, combination of IL-17A and IL-22 significantly reduced the generation of Th1 cells and the production of interferon (IFN)-γ from healthy donor or AML patient peripheral blood mononuclear cells.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Show MeSH

Related in: MedlinePlus

Generation and differentiation of Th17 cells from peripheral blood (PB) and bone marrow (BM) regulated by interleukin (IL)-1β, IL-6, and IL-23. Elevated levels of Th17-producing cytokines (a) and Th17-associated proinflammatory cytokines (b) in PB and BM samples from acute myeloid leukemia (AML) patients were determined by ELISA. (c) Th17 cells detected in naive CD4+ T cells purified from AML patients after stimulation with indicated cytokines. The naive CD4+ T cells were isolated from PB of AML patients and subsequently stimulated by plate-bound anti-CD3 and soluble anti-CD28 mAbs with or without the indicated cytokines. After 7 days, the cells were restimulated with phorbol 12-myristate13-acetate (PMA) and ionomycin in the presence of brefeldin A and analyzed for intercellular IL-17A expression. The data were expressed as mean ± SEM representing four independent experiments from different AML patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317867&req=5

fig03: Generation and differentiation of Th17 cells from peripheral blood (PB) and bone marrow (BM) regulated by interleukin (IL)-1β, IL-6, and IL-23. Elevated levels of Th17-producing cytokines (a) and Th17-associated proinflammatory cytokines (b) in PB and BM samples from acute myeloid leukemia (AML) patients were determined by ELISA. (c) Th17 cells detected in naive CD4+ T cells purified from AML patients after stimulation with indicated cytokines. The naive CD4+ T cells were isolated from PB of AML patients and subsequently stimulated by plate-bound anti-CD3 and soluble anti-CD28 mAbs with or without the indicated cytokines. After 7 days, the cells were restimulated with phorbol 12-myristate13-acetate (PMA) and ionomycin in the presence of brefeldin A and analyzed for intercellular IL-17A expression. The data were expressed as mean ± SEM representing four independent experiments from different AML patients.

Mentions: We evaluated the levels of Th17-producing cytokines to further confirm increased existence of Th17 cells in AML patients. Significant elevation of IL-17A, IL-22, and IL-23, three cytokines secreted by Th17 cells, were observed in both PB and BM from untreated AML patients compared with those from healthy donors as measured by ELISA (Fig. 3a). We next evaluated other cytokines that had been reported to associate with the generation and differentiation of human Th17 cells. As shown in Figure 3(b), higher levels of IL-1β, IL-6, and TGF-β1 were observed in PB and BM from AML patients compared with those from healthy donors. These results suggested that these proinflammatory cytokines present in AML BM microenvironment might modulate the generation and differentiation of Th17 cells.


Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.

Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S - Cancer Sci. (2014)

Generation and differentiation of Th17 cells from peripheral blood (PB) and bone marrow (BM) regulated by interleukin (IL)-1β, IL-6, and IL-23. Elevated levels of Th17-producing cytokines (a) and Th17-associated proinflammatory cytokines (b) in PB and BM samples from acute myeloid leukemia (AML) patients were determined by ELISA. (c) Th17 cells detected in naive CD4+ T cells purified from AML patients after stimulation with indicated cytokines. The naive CD4+ T cells were isolated from PB of AML patients and subsequently stimulated by plate-bound anti-CD3 and soluble anti-CD28 mAbs with or without the indicated cytokines. After 7 days, the cells were restimulated with phorbol 12-myristate13-acetate (PMA) and ionomycin in the presence of brefeldin A and analyzed for intercellular IL-17A expression. The data were expressed as mean ± SEM representing four independent experiments from different AML patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317867&req=5

fig03: Generation and differentiation of Th17 cells from peripheral blood (PB) and bone marrow (BM) regulated by interleukin (IL)-1β, IL-6, and IL-23. Elevated levels of Th17-producing cytokines (a) and Th17-associated proinflammatory cytokines (b) in PB and BM samples from acute myeloid leukemia (AML) patients were determined by ELISA. (c) Th17 cells detected in naive CD4+ T cells purified from AML patients after stimulation with indicated cytokines. The naive CD4+ T cells were isolated from PB of AML patients and subsequently stimulated by plate-bound anti-CD3 and soluble anti-CD28 mAbs with or without the indicated cytokines. After 7 days, the cells were restimulated with phorbol 12-myristate13-acetate (PMA) and ionomycin in the presence of brefeldin A and analyzed for intercellular IL-17A expression. The data were expressed as mean ± SEM representing four independent experiments from different AML patients.
Mentions: We evaluated the levels of Th17-producing cytokines to further confirm increased existence of Th17 cells in AML patients. Significant elevation of IL-17A, IL-22, and IL-23, three cytokines secreted by Th17 cells, were observed in both PB and BM from untreated AML patients compared with those from healthy donors as measured by ELISA (Fig. 3a). We next evaluated other cytokines that had been reported to associate with the generation and differentiation of human Th17 cells. As shown in Figure 3(b), higher levels of IL-1β, IL-6, and TGF-β1 were observed in PB and BM from AML patients compared with those from healthy donors. These results suggested that these proinflammatory cytokines present in AML BM microenvironment might modulate the generation and differentiation of Th17 cells.

Bottom Line: In addition, combination of IL-17A and IL-22 significantly reduced the generation of Th1 cells and the production of interferon (IFN)-γ from healthy donor or AML patient peripheral blood mononuclear cells.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Show MeSH
Related in: MedlinePlus